Website
News25/Ratings5
News · 26 weeks59-70%
2025-10-262026-04-19
Mix3990d
- Other13(33%)
- Insider13(33%)
- SEC Filings11(28%)
- Earnings2(5%)
Latest news
25 items- SECSEC Form S-8 filed by BrainsWay Ltd.S-8 - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form S-8 POS filed by BrainsWay Ltd.S-8 POS - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form 20-F filed by BrainsWay Ltd.20-F - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) TherapyBURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today highlighted the growing trend across the U.S. payer landscape of coverage policies that allow appropriately trained nurse practitioners to administer Transcranial Magnetic Stimulation (TMS) therapy. A growing number of commercial insurers, Medicare Administrative Contractors (MACs), and government payers now permit psychiatric mental health nurse practitioners (PMHNPs) to administer TMS therapy, including Deep TMS™, when practicing in accordance with app
- PRBrainsWay to Participate in the 25th Annual Needham Virtual Healthcare ConferenceBURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulati
- SECSEC Form SCHEDULE 13G filed by BrainsWay Ltd.SCHEDULE 13G - Brainsway Ltd. (0001505065) (Subject)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDDBURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. ("Neurolief"). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief's Proliv™Rx system, a milestone defined under the terms of BrainsWay's August 2025 strategic investment transaction with Neurolief. "Our strategic investments in Neurolief are part of our long-term mi
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental HealthBURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. The investment was made following Axis's achievement of a predefined revenue performance milestone under the terms of the two companies' August 2025 strategic equity financing agreement. "We are excited for the Axis tea
- INSIDERSEC Form 3 filed by new insider Zangen Abraham3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mitrany Rayten Michal Ety3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zacut David3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Marom Ido3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sarid Karen3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lushi Avner3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rozenfeld Naomi3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Levy Hadar3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Roth Yiftach3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hanlon Colleen3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Moiseyev Gilad3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Boehm Amiram3 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shulkin Jonathan K3 - Brainsway Ltd. (0001505065) (Issuer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)